Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint® and BluePrint’s® Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients

New data from the I-SPY 2 trial highlights residual cancer burden as a prognostic indicator for long-term outcomes in patients pre-selected using MammaPrint NBRST trial reports three-year patient outcomes showing that the use of MammaPrint and BluePrint testing in the … Continued

Functional Subtyping with BluePrint 80-gene profile identifies distinct triple positive subtypes with and without trastuzumab/pertuzumab/chemo-sensitivity

Author(s): Pat Whitworth, Peter Beitsch, Paul Baron, Michael C Rotkis, James V Pellicane, Mary Murray, Carrie L Dul, Angela M Mislowsky, Charles H Nash, Paul D Richards, Laura A Lee, Lisette Stork-Sloots, Femke de Snoo, Sarah Untch, Mark Gittleman, Stephanie Akbari, Jennifer Beatty

Background and Aim Classification into molecular subtypes is important for the selection of therapy for patients with breast cancer. Previous analyses demonstrated that breast cancer subtypes have distinct clinical outcome (Glück, BCRT 2013). The aim of the prospective NBRST study is to compare a … Continued

Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Publication Name: Annals of Surgical Oncology

Author(s): Whitworth P, Stork-Sloots L, de Snoo FA, Richards P, Rotkis M, Beatty J, Mislowsky A, Pellicane JV, Nguyen B, Lee L, Nash C, Gittleman M, Akbari S, Beitsch PD.

PURPOSE: The purpose of the NBRST study is to compare a multigene classifier to conventional immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) subtyping to predict chemosensitivity as defined by pathological complete response (pCR) or endocrine sensitivity as defined by partial response. … Continued